Seeking to change lives with next generation peptide therapeutics

Q1 2024 Financial Results

May 16, 2024
2:00pm CET (8:00am ET)
Read more

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% ...

Zealand Pharma’s Obesity R&D Event

Phase 3 clinical trials to investigate survodutide for people living with obesity and overweight…

Our research

Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more

Clinical pipeline

Advancing development programs in rare diseases and obesity. See our pipeline

About Zealand

Get a brief overview on Zealand and learn more about our company. Read more


Information for analysts, investors, and shareholders.
Read more